ArticleERJ open research2025
Serum immunoglobulin A as a biomarker for respiratory syncytial virus infection in children aged <2 years.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.Microbiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Past research suggested respiratory syncytial virus (RSV) specific serum immunoglobulin A (IgA) antibodies as a biomarker of previous RSV infections in young infants accounting for maternal immunity. This study aimed to confirm this association and to establish a serological threshold for discriminating RSV-naïve infants from those who have experienced RSV. Material and methods: This study involves 135 infants from the LoewenKIDS study with nasal swabs collected at each acute respiratory infection, and serum samples collected at ages 1 and 2 years. RSV presence in swabs was ascertained by reverse transcriptase PCR; RSV-specific IgG and IgA antibody levels against five different structural proteins and RSV neutralising antibodies were measured in sera. Robust Mixture Discriminant Analysis was used to determine the cut-off values and account for false negatives. Results: Of 135 included infants, 131 had available data at year 1 (Y1) and 95 at year 2 (Y2). Pre-F IgA concentrations were higher in infants with PCR-confirmed RSV infections. There was a further increase in IgA, IgG and neutralising antibody titre concentrations from Y1 to Y2 consistent with re-infections. Based on robust mixture discriminant analysis, the cut-off values of pre-F IgA level indicative of past RSV infection were 0.23 AU·mL Conclusion: This study shows that in children aged <2 years, a previous RSV infection is accompanied by serum pre-F IgA antibody levels above 0.22 AU·mL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.